Enhancement of Antibody Response to an Antigonadotropin Vaccine by use of Adjuvants
Initial clinical trials of an antipregnancy vaccine consisting of the β-subunit of human chorionic gonadotropin linked to tetanus toxoid (β-hCG-TT) and adsorbed on Al (OH)3 resulted in low and short-lived antibody titers in some of the women studied (1,2). It was therefore judged necessary to find ways to enhance the antibody response. Approaches explored included the use of other adjuvants to supplement the aluminum hydroxide and the use of modified vehicles. The effectiveness of these expedients was evaluated by vaccinating rabbits and measuring the concentration in serum of antibodies capable of binding labeled hCG. In selected instances, the ability of the antiserum to inhibit stimulation by hCG of uterine growth in immature rats was also measured. Some of the findings have been reported in earlier publications (3,4). They are summarized and extended in the present review.
KeywordsHuman Chorionic Gonadotropin Tetanus Toxoid Sorbitan monoOleate Aluminum Potassium Sulfate Streptococcal Preparation
Unable to display preview. Download preview PDF.
- 1.Nash, H., Talwar, G. P., Segal, S., Luukkainen, T., Johansson, E.D.B., Vasquez, J., Coutinho, E., and Sundaram, K. Observations on the antigenicity and clinical effects of a candidate antipregnancy vaccine: β-subunit of human chorionic gonadotropin linked to tetanus toxoid. Fertil. Steril. 34: 328 (1980).PubMedGoogle Scholar
- 15.Friedman, H. Immuncmodulation by small molecular weight bacterial products. Adv. Exptl. Med. Biol. 166: 199 (1983).Google Scholar